Latest news

Debiopharm International SA and EORTC announce a collaboration to investigate Triptorelin for treatment of Salivary Gland Cancers

Debiopharm International SA and Arbor Pharmaceuticals, LLC announce their US commercialization partnership for Triptorelin in Central Precocious Puberty

United Laboratories Inc. and Debiopharm International SA announce the launch of Pamorelin® LA in the Philippines

Challenge Debiopharm Inartis: appel à projets

EMA grants Orphan Drug Designation to Debiopharm International SA’s IAP inhibitor Debio 1143 in the treatment of Ovarian Cancer

Debiopharm International SA’s partner Yakult Honsha Co, Ltd. announces Elplat® approbation in gastric cancer in Japan

Debiopharm International SA presents positive preliminary results from Phase 1 trials in the development of the IAP inhibitor Debio 1143…

The Japanese Cancer Association and Debiopharm Group Announce Winners of the 2015 JCA-Mauvernay Award

Debiopharm Group™ inaugure son site de production et son laboratoire de recherche après 18 mois de travaux, à Martigny.